We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+42.63%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$906M
AUM Growth
-$90.1M
Cap. Flow
-$241M
Cap. Flow %
-26.64%
Top 10 Hldgs %
57.8%
Holding
54
New
5
Increased
4
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$17.3M
2
VRNA
Verona Pharma
VRNA
+$12.6M
3
TERN
Terns Pharmaceuticals
TERN
+$12M
4
PCVX icon
Vaxcyte
PCVX
+$10.3M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.87M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$183M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$62.4M
3
HRMY icon
Harmony Biosciences
HRMY
+$33.8M
4
VTYX
Ventyx Biosciences
VTYX
+$12.5M
5
CLDX icon
Celldex Therapeutics
CLDX
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.5%
2 Materials 2.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRMY icon
1
Harmony Biosciences
HRMY
$2.07B
$151M 16.63%
3,400,261
-693,524
-17% -$33.8M
TIL icon
2
Instil Bio
TIL
$49.4M
$60.4M 6.67%
624,339
– –
VTYX
3
DELISTED
Ventyx Biosciences
VTYX
$47.3M 5.23%
1,355,861
-565,865
-29% -$12.5M
VRNA
4
DELISTED
Verona Pharma
VRNA
$43.4M 4.8%
4,249,918
+1,500,000
+55% +$12.6M
ALXO icon
5
ALX Oncology
ALXO
$268M
$40.4M 4.46%
4,220,048
– –
TARS icon
6
Tarsus Pharmaceuticals
TARS
$2.57B
$38.7M 4.28%
2,262,200
-50,168
-2% -$797K
SVA
7
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 4.21%
5,900,000
– –
GERN icon
8
Geron
GERN
$930M
$35.7M 3.94%
15,238,095
– –
TERN
9
DELISTED
Terns Pharmaceuticals
TERN
$34.7M 3.84%
5,899,372
+3,224,239
+121% +$12M
VRDN icon
10
Viridian Therapeutics
VRDN
$2.15B
$34M 3.76%
1,660,019
+360,019
+28% +$6.47M
COGT icon
11
Cogent Biosciences
COGT
$6.95B
$28.1M 3.1%
1,883,941
-37,000
-2% -$507K
RLMD icon
12
Relmada Therapeutics
RLMD
$549M
$26.4M 2.92%
713,238
+7,356
+1% +$204K
ALLK
13
DELISTED
Allakos
ALLK
$25.2M 2.78%
+4,120,134
New +$17.3M
AMRS
14
DELISTED
Amyris Inc.
AMRS
$22.6M 2.5%
7,750,828
-3,891,367
-33% -$10.6M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$22.3M 2.46%
1,533,559
– –
KDNY
16
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$17.1M 1.89%
872,151
– –
ASND icon
17
Ascendis Pharma A/S
ASND
$16.7B
$15.1M 1.66%
146,025
– –
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
$14.7M 1.62%
2,937,093
– –
VERA icon
19
Vera Therapeutics
VERA
$2.39B
$14.2M 1.57%
666,666
– –
ACRS icon
20
Aclaris Therapeutics
ACRS
$744M
$14.1M 1.56%
898,631
– –
IMPL
21
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$14M 1.55%
2,884,789
– –
CINC
22
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$11.5M 1.27%
+349,237
New +$9.87M
BLU
23
DELISTED
BELLUS Health Inc.
BLU
$10.7M 1.19%
1,017,152
– –
LEGN icon
24
Legend Biotech
LEGN
$3.68B
$9.97M 1.1%
244,375
– –
PCVX icon
25
Vaxcyte
PCVX
$7.88B
$9.71M 1.07%
+404,508
New +$10.3M
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Vivo Capital held 54 positions worth $906M, down 9% from $996M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Vivo Capital withdrew a net $241M in Q3 2022, closing 3 positions and reducing 7 holdings. Its most notable exit was Sierra Oncology, Inc. Common Stock, an estimated $183M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Materials.

Against the trend, Vivo Capital opened a new position in Allakos worth $25.2M.

  • Vivo Capital's largest Q3 2022 buy was Allakos: 4,120,134 shares worth $25.2M.
  • Vivo Capital added most to Verona Pharma in Q3 2022, an estimated $12.6M increase.
  • Vivo Capital's biggest Q3 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $62.4M.
  • Vivo Capital fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $183M.
  • Vivo Capital's ten largest holdings make up 58% of its $906M portfolio in Q3 2022.
  • Vivo Capital opened 5 new positions and closed 3 in Q3 2022.
  • Vivo Capital's portfolio value fell 9% quarter-over-quarter to $906M.

Based on Vivo Capital's 13F filing for Q3 2022, filed 14 Nov 2022.